| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |